(Circulation. 2001;103:2555.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
Ability of Recombinant Factor VIIa to Generate Thrombin During Inhibition of Tissue Factor in Human Subjects
From the Department of Vascular Medicine and Internal Medicine, Academic Medical Center, University of Amsterdam, Netherlands (P.W.F., M.L., D.B., T.K., M.S., H.R.B.); Boston VA Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass (K.A.B., S.B.); and Corvas International, Inc, San Diego, Calif (G.P.V., W.E.R.).
Correspondence to Marcel Levi, MD, Department of Vascular Medicine and Internal Medicine (F-4), Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands. E-mail m.m.levi{at}amc.uva.nl
Background—In view of the central role of the tissue factor–factor VIIa pathway in the initiation of blood coagulation, novel therapeutic strategies aimed at inhibiting this catalytic complex are currently being evaluated. A limitation of this new class of anticoagulants may be the lack of an appropriate strategy to reverse the effect if a bleeding event occurs. The aim of this study was to investigate the in vivo potential of recombinant factor VIIa (rVIIa) to induce thrombin generation in healthy subjects pretreated with recombinant nematode anticoagulant protein c2, a specific inhibitor of the tissue factor–factor VIIa complex, in a double-blind randomized crossover study.
Methods and Results—Administration of nematode anticoagulant protein c2 (3.5 µg/kg) caused a prolongation of the prothrombin time from 13.7±0.6 to 16.9±1.2 seconds. The subsequent injection of rVIIa (90 µg/kg) resulted in an immediate and complete correction of the prothrombin time and a marked generation of thrombin, reflected by increased levels of prothrombin activation fragment F1+2 and thrombin-antithrombin complexes from 0.75±0.64 to 3.29±6.3 nmol/L and from 2.4±0.6 to 10.7±3.9 µg/mL, respectively. Factor X and IX activation peptides showed a 3.5-fold and a 3.8-fold increase, respectively, after the administration of rVIIa in the presence of nematode anticoagulant protein c2.
Conclusions—During treatment with an inhibitor of the tissue factor–factor VIIa complex, the infusion of rVIIa resulted in thrombin generation. Our results indicate that rVIIa may be a good candidate as an antidote for inhibitors of tissue factor.
Key Words: anticoagulants • coagulation • thrombosis • drugs • inhibitors
This article has been cited by other articles:
 |
|
 |
|
  M. A. Crowther and T. E. Warkentin Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents Blood, May 15, 2008; 111(10): 4871 - 4879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Giugliano, S. D. Wiviott, P. H. Stone, D. I. Simon, M. J. Schweiger, A. Bouchard, M. A. Leesar, M. A. Goulder, S. R. Deitcher, C. H. McCabe, et al. Recombinant Nematode Anticoagulant Protein c2 in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: The ANTHEM-TIMI-32 Trial J. Am. Coll. Cardiol., June 26, 2007; 49(25): 2398 - 2407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Levy Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation Am. J. Health Syst. Pharm., September 15, 2005; 62(18_Supplement_4): S15 - S19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Roberts, D. M. Monroe, and G. C. White The use of recombinant factor VIIa in the treatment of bleeding disorders Blood, December 15, 2004; 104(13): 3858 - 3864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M J Schultz, J Millo, M Levi, C E Hack, G J Weverling, C S Garrard, and T van der Poll Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia Thorax, February 1, 2004; 59(2): 130 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tranholm, K. Kristensen, A. T. Kristensen, C. Pyke, R. Rojkjaer, and E. Persson Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A Blood, November 15, 2003; 102(10): 3615 - 3620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. M. Moons, R. J. G. Peters, N. R. Bijsterveld, J. J. Piek, M. H. Prins, G. P. Vlasuk, W. E. Rote, and H. R. Buller Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplastyAppendix J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2147 - 2153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. de Jonge, P. W. Friederich, G. P. Vlasuk, W. E. Rote, M. B. Vroom, M. Levi, and T. van der Poll Activation of Coagulation by Administration of Recombinant Factor VIIa Elicits Interleukin 6 (IL-6) and IL-8 Release in Healthy Human Subjects Clin. Vaccine Immunol., May 1, 2003; 10(3): 495 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. R. Bijsterveld, A. H. Moons, S. M. Boekholdt, B. E. van Aken, H. Fennema, R. J.G. Peters, J. C.M. Meijers, H. R. Buller, and M. Levi Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers Circulation, November 12, 2002; 106(20): 2550 - 2554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Buddai, L. Toulokhonova, P. W. Bergum, G. P. Vlasuk, and S. Krishnaswamy Nematode Anticoagulant Protein c2 Reveals a Site on Factor Xa That Is Important for Macromolecular Substrate Binding to Human Prothrombinase J. Biol. Chem., July 12, 2002; 277(29): 26689 - 26698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Dietrich, M. Spannagl, H. G. D. Hendriks, J. M. A. A. van der Maaten, J. Th. M. de Wolf, and J. van der Meer Caveat Against the Use of Activated Recombinant Factor VII for Intractable Bleeding in Cardiac Surgery * Response Anesth. Analg., May 1, 2002; 94(5): 1369 - 1371. [Full Text] [PDF]
|
|
|
|
|
|
A. Lee, G. Agnelli, H. Buller, J. Ginsberg, J. Heit, W. Rote, G. Vlasuk, L. Costantini, J. Julian, P. Comp, et al. Dose-Response Study of Recombinant Factor VIIa/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement Circulation, July 3, 2001; 104(1): 74 - 78. [Abstract] [Full Text] [PDF]
|
|